Active Biotech: Interim report January - March 2017

April 27, 2017 08:30 (CEST)Regulatory

Laquinimod

  • The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
  • The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
  • The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
  • Orphan Drug Designation granted for laquinimod for the treatment of Huntington's disease by the US Food and Drug Administration (FDA)

ANYARA     

  • Project proceeding according to plan

Tasquinimod, paquinimod and SILC

  • Out-licensing activities are continuing
  • The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
  • Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
  • Product patent for SILC substances granted by the European Patent Office

Financial summary

SEK M Jan.-Mar.   Full-year
  2017 2016    2016
Net sales 4.7   3.9     19.0
Operating loss -14.6 -16.1     -55.1
Loss after tax -15.8 -16.8     -59.6
Loss per share, before and after dilution (SEK) -0.16 -0.19   -0.65
Cash and cash equivalents (at close of period) 62.7  76.5     77.7
         
  • Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

  Tomas Leanderson, President and CEO
  Tel: +46 (0) 46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00

 

The report is also available at www.activebiotech.com.

Active Biotech AB Interim report January - March 2017